Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Columbia University
With
Breast Cancer Research Foundation
Breast cancer is the most common cancer and the second leading cause of cancer death among women in the United States. Several epidemiologic studies have found an increased risk of breast cancer in women with type 2 diabetes. This association appears to be mediated by a state of hyperinsulinemia and insulin resistance. Population based studies have also found a decreased risk of cancer in diabetic patients taking metformin, an oral biguanide derivative. Proposed mechanisms include its effect on lowering serum insulin levels as well as modulation of cellular signaling pathways which inhibit tumor cellular proliferation.
Age
21–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically-confirmed operable invasive breast cancer or ductal carcinoma in situ (DCIS) who undergo core needle biopsy followed by surgical excision at least 2 weeks after enrollment
Body mass index \> 25
Age ≥ 21 years
No prior chemotherapy, radiation therapy, or surgery within 6 months of study entry
Signed informed consent
You may not be if
History of diabetes mellitus requiring medical therapy
Treatment with other investigational drugs within 6 months of study entry
Significant renal impairment with a creatinine \> 1.4 mg/dl
Other serious intercurrent medical illness
Clareo Health | Pre-Surgical Study: Effect of Metformin on Breast Cancer Proliferation
